DK2139557T3 - Elektronisk system til påvirkning af cellulære funktioner hos et varmblodet pattedyrindivid - Google Patents
Elektronisk system til påvirkning af cellulære funktioner hos et varmblodet pattedyrindivid Download PDFInfo
- Publication number
- DK2139557T3 DK2139557T3 DK08734777.9T DK08734777T DK2139557T3 DK 2139557 T3 DK2139557 T3 DK 2139557T3 DK 08734777 T DK08734777 T DK 08734777T DK 2139557 T3 DK2139557 T3 DK 2139557T3
- Authority
- DK
- Denmark
- Prior art keywords
- frequencies
- treat
- cancer
- amplitude
- amplitude modulation
- Prior art date
Links
- 230000003915 cell function Effects 0.000 title claims description 8
- 206010028980 Neoplasm Diseases 0.000 claims description 23
- 201000011510 cancer Diseases 0.000 claims description 15
- 210000001519 tissue Anatomy 0.000 claims description 11
- 230000005540 biological transmission Effects 0.000 claims description 6
- 230000006461 physiological response Effects 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 5
- 238000010521 absorption reaction Methods 0.000 claims description 4
- 206010025323 Lymphomas Diseases 0.000 claims description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 3
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 3
- 230000001684 chronic effect Effects 0.000 claims description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 3
- 238000005259 measurement Methods 0.000 claims description 3
- 230000000955 neuroendocrine Effects 0.000 claims description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 3
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 2
- 208000017604 Hodgkin disease Diseases 0.000 claims description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
- 208000018142 Leiomyosarcoma Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 206010027406 Mesothelioma Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 230000006698 induction Effects 0.000 claims description 2
- 201000010982 kidney cancer Diseases 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 230000035755 proliferation Effects 0.000 claims description 2
- 201000002510 thyroid cancer Diseases 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 102000052609 BRCA2 Human genes 0.000 claims 1
- 108700020462 BRCA2 Proteins 0.000 claims 1
- 201000003741 Gastrointestinal carcinoma Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 230000005907 cancer growth Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 201000002313 intestinal cancer Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 238000012544 monitoring process Methods 0.000 claims 1
- 238000011282 treatment Methods 0.000 description 61
- 239000000523 sample Substances 0.000 description 19
- 230000001225 therapeutic effect Effects 0.000 description 12
- 238000002560 therapeutic procedure Methods 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 230000010261 cell growth Effects 0.000 description 8
- 238000010168 coupling process Methods 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 7
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 7
- 230000004044 response Effects 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 6
- 210000003169 central nervous system Anatomy 0.000 description 6
- 230000008878 coupling Effects 0.000 description 6
- 238000005859 coupling reaction Methods 0.000 description 6
- 230000005672 electromagnetic field Effects 0.000 description 6
- 201000010099 disease Diseases 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- 206010061309 Neoplasm progression Diseases 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 230000007257 malfunction Effects 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 230000003595 spectral effect Effects 0.000 description 3
- 230000005751 tumor progression Effects 0.000 description 3
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 238000004891 communication Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 230000007958 sleep Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 238000011277 treatment modality Methods 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 206010055113 Breast cancer metastatic Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 208000011688 Generalised anxiety disease Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028116 Mucosal inflammation Diseases 0.000 description 1
- 201000010927 Mucositis Diseases 0.000 description 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 1
- 206010037218 Psychopathic personality Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 208000037844 advanced solid tumor Diseases 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 208000024823 antisocial personality disease Diseases 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000027288 circadian rhythm Effects 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 210000000883 ear external Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 208000029364 generalized anxiety disease Diseases 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 238000002847 impedance measurement Methods 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000007479 molecular analysis Methods 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 208000019906 panic disease Diseases 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 208000028173 post-traumatic stress disease Diseases 0.000 description 1
- 208000037821 progressive disease Diseases 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 230000003304 psychophysiological effect Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 201000009032 substance abuse Diseases 0.000 description 1
- 231100000736 substance abuse Toxicity 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000009121 systemic therapy Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/40—Applying electric fields by inductive or capacitive coupling ; Applying radio-frequency signals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/02—Radiation therapy using microwaves
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/02—Radiation therapy using microwaves
- A61N5/022—Apparatus adapted for a specific treatment
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pathology (AREA)
- Electrotherapy Devices (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Radiation-Therapy Devices (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Magnetic Treatment Devices (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
- Magnetic Resonance Imaging Apparatus (AREA)
- Current-Collector Devices For Electrically Propelled Vehicles (AREA)
- Plural Heterocyclic Compounds (AREA)
Claims (18)
1. Elektronisk system (11), der kan aktiveres med elektrisk strøm, til anvendelse ved hæmning af vækst af kræftceller eller proliferation deraf hos et varmblodet pattedyrindivid, omfattende: et eller flere kontrollerbare lavenergi-elektromagnetiske energigenerator-kredsløb (29) til generering af et eller flere højfrekvente bærersignaler, en eller flere dataprocessorer eller integrerede kredsløb (21), som omfatter eller kommunikerer med et eller flere generatorkredsløb (29), og som skal modtage kontrolinformation fra en kilde af kontrolinformation, som er en applikationslagringsindretning eller computer (52), hvor et eller flere generatorkredsløb (29) omfatter en eller flere amplitudemo-dulationskontrolsignalgeneratorer (34) til kontrol af amplitudemodulerede variationer i det ene eller de flere højfrekvente bærersignaler, hvor et eller flere generatorkredsløb (29) omfatter en eller flere programmerbare amplitudemodulationsfrekvenskontrolsignalgeneratorer (31) til kontrol af den frekvens, ved hvilken amplitudemodulationerne genereres, hvor systemet (11) yderligere omfatter en forbindelses- eller tilkoblingsposition (12a) til forbindelse med en elektrisk ledende applikator (12,13), hvor den ene eller de flere programmerbare amplitudemodulationsfrekvens-kontrolgeneratorer (31) er udformet til nøjagtigt at kontrollere frekvensen af amplitudemodulationer til inden for en nøjagtighed på mindst 1000 ppm i forhold til en eller flere bestemte eller forudbestemte referenceamplitudemodu-lationsfrekvenser udvalgt fra inden for et område på 0,01 Hz til 150 kHz og kendetegnet ved, at kilden af kontrolinformation (52) omfatter referenceamplitudemodulationsfre-kvenskontrolinformation, som omfatter mindst 50 % af de nøjagtigt definerede referenceamplitudemodulationsfrekvenser, der er angivet under et af de nedenfor anførte punkter 1 til 17, hvor applikatoren (12, 13) er udformet til at blive anvendt ved kontakt eller nærmest induktion på det varmblodede pattedyrindivid en eller flere amplitude-modulerede lavenergiudsendelser ved en programkontrolleret frekvens, hvilket resulterer i lave absorptionsniveauer, i det væsentlige mindre end 1,6 milliW/g vægt af levende væv, og hvor amplituden moduleres ved sekventiel eller simultan anvendelse af de mindst 50 % af referenceamplitudemodulationsfrekvenserne.
1. AM-frekvenser anvendt til behandling af brystkræft
2. AM-frekvenser anvendt til behandling af leverkræft
3. AM-frekvenser anvendt til behandling af æggestokkræft
4. AM-frekvenser anvendt til behandling af prostatakræft
5. AM-frekvenser anvendt til behandling af nyrekræft
6. AM-frekvenser anvendt til behandling af cancer i skjoldbruskkirtlen
7. AM-frekvenser anvendt til behandling af blærekræft
8. AM-frekvenser anvendt til behandling af tarmkræft
9. AM-frekvenser anvendt til behandling af pancreas-cancer
10. AM-frekvenser anvendt til behandling af lungekræft
11. AM-frekvenser anvendt til behandling af leiomyosarcom
12. AM-frekvenser anvendt til behandling af mesotheliom
13. AM-frekvenser anvendt til behandling af neuro-endokrin
14. AM-frekvenser anvendt til behandling af leukæmi og kronisk lymfekræft
15. AM-frekvenser anvendt til behandling af myelom, multipel cancer
16. AM-frekvenser anvendt til behandling af Hodgkins sygdom
17. AM-frekvenser anvendt til behandling af kræft i hjernen
2. System (11) ifølge krav 1, i hvilket frekvensen af den ene eller de flere genererede amplitudemodulationer kan kontrolleres op til inden for en nøjagtighed af 100 ppm i forhold til den ene eller de flere bestemte eller forudbestemte referenceamplitudemodulationsfrekvenser.
3. System (11) ifølge krav 2, i hvilket frekvensen af den ene eller de flere genererede amplitudemodulationer kan kontrolleres op til inden for en nøjagtighed af 10 ppm i forhold til den ene eller de flere bestemte eller forudbestemte referenceamplitudemodulationsfrekvenser.
4. System (11) ifølge krav 3, i hvilket frekvensen af den ene eller de flere genererede amplitudemodulationer kan kontrolleres op til inden for en nøjagtighed af 1 ppm i forhold til den ene eller de flere bestemte eller forudbestemte referenceamplitudemodulationsfrekvenser.
5. System (11) ifølge et af de foregående krav, i hvilket de genererede amplitudemodulerede lavenergi-elektromagnetiske udsendelser opretholdes på en stabilitet under udsendelse på mindst 10'5.
6. System (11) ifølge krav 5, i hvilket der opretholdes en stabilitet på mindst 10'6.
7. System (11) ifølge krav 6, i hvilket der opretholdes en stabilitet på mindst 10'7.
8. System (11) ifølge et af de foregående krav, i hvilket det ene eller de flere kontrollerbare generatorkredsløb (29) kan kontrolleres ved hjælp af amplitu-demodulationskontrolsignaler, som fører til diverse former af amplitudemodulationsbølgeformer, der genereres.
9. System (11) ifølge krav 8, i hvilket amplitudemodulationsbølgeformerne er udvalgt blandt sinusoidale, kvadratiske, triangulære eller flere kombinationer deraf.
10. System (11) ifølge krav 8 eller krav 9, i hvilket det ene eller de flere kontrollerbare generatorkredsløb (29) kan kontrolleres ved hjælp af amplitude-modulationskontrolsignaler, som genererer en flerhed af amplitudemodulationsbølgeformer, enten sekventielt eller simultant.
11. System (11) ifølge et af de foregående krav, i hvilket de højfrekvente bærersignaler, der skal genereres af det ene eller de flere generatorkredsløb (29), er udvalgt fra en eller flere frekvenser udvalgt blandt ca. 27 MHz, 433 MHz og 900 MHz
12. A system (11) ifølge et af de foregående krav, i hvilket systemet (11) omfatter et eller flere interfaces eller modtagermidler (16), der kommunikerer med den ene eller de flere dataprocessorer eller integrerede kredsløb (21), og i hvilket kontrolinformationen kan overføres til det ene eller de flere interfaces eller modtagermidler (16) og således til den ene eller de flere dataprocessorer eller integrerede kredsløb (21) for at muliggøre kommandosignaler, der kan reagere på modtaget kontrolinformation, der skal kommunikeres til det ene eller de flere generatorkredsløb (29) af den ene eller de flere dataprocessorer eller integrerede kredsløb (21).
13. System (11) ifølge krav 12, i hvilket kontrolinformationen kan overføres eller transmitteres via telefonen, Internettet, radio eller andre midler, til den ene eller de flere dataprocessorer eller integrerede kredsløb (21) via det ene eller de flere interfaces eller modtagermidler (16), der kommunikerer med den ene eller de flere dataprocessorer eller integrerede kredsløb (21).
14. System (11) ifølge krav 12 eller krav 13, i hvilket kontrolinformationen lagres i en informationslagringsindretning (52), og i hvilket kontrolinformationen kan overføres til den ene eller de flere dataprocessorer eller integrerede kredsløb (21) via et eller flere interfaces (16), der kommunikerer med den ene eller de flere dataprocessorer eller integrerede kredsløb (21).
15. System (11) ifølge et af de foregående krav, i hvilket systemet omfatter en brugeridentifikationsindretning (21a), der kommunikerer med mindst en af den ene eller de flere dataprocessorer eller integrerede kredsløb (21), der gør det muligt for systemet (11) at blive aktiveret eller anvendt kun af brugeren.
16. System (11) ifølge et af de foregående krav, hvilket omfatter en monitor (54), der omfatter at overvåge software til overvågning af amplituden og amplitudemodulationsfrekvensen af de amplitudemodulerede lavenergi-elektromagnetiske udsendelser, der genereres af den ene eller de flere generatorkredsløb (29).
17. System (11) ifølge et af de foregående krav, i hvilket den bestemte eller forudbestemte amplitudemodulationsfrekvenskontrolinformation bestemmes eller forudbestemmes ved hjælp af en bio-feedbackproces, der omfatter observationer eller målinger af fysiologiske reaktioner hos individet, når eller i løbet af den tid, hvor cellulære funktioner hos individet aktiveres, når individet udsættes for udsendelser med højfrekvente bærersignaler, der er amplitudemoduleret med en serie af amplitudemodulationsfrekvenser
18. System (11) ifølge krav 17, i hvilket de bestemte eller forudbestemte frekvenser anvendes som en modus for at identificere typen af en tumor eller cancer, som forefindes i et varmblodet pattedyrindivid.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07006320A EP1974769A1 (en) | 2007-03-27 | 2007-03-27 | Electronic system for influencing cellular functions in a warm-blooded mammalian subject |
| PCT/EP2008/002379 WO2008116640A2 (en) | 2007-03-27 | 2008-03-26 | Electronic system for influencing cellular functions in a warm-blooded mammalian subject |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2139557T3 true DK2139557T3 (da) | 2015-08-10 |
Family
ID=38117246
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK08734777.9T DK2139557T3 (da) | 2007-03-27 | 2008-03-26 | Elektronisk system til påvirkning af cellulære funktioner hos et varmblodet pattedyrindivid |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US20100042168A1 (da) |
| EP (2) | EP1974769A1 (da) |
| JP (1) | JP5435240B2 (da) |
| KR (1) | KR101474582B1 (da) |
| CN (1) | CN101663065B (da) |
| AU (1) | AU2008232041C1 (da) |
| BR (1) | BRPI0810084B1 (da) |
| CA (1) | CA2682322C (da) |
| DK (1) | DK2139557T3 (da) |
| ES (1) | ES2545103T3 (da) |
| HU (1) | HUE027033T2 (da) |
| IL (1) | IL201099A (da) |
| MX (1) | MX2009010425A (da) |
| PL (1) | PL2139557T3 (da) |
| PT (1) | PT2139557E (da) |
| RU (1) | RU2594824C2 (da) |
| SA (1) | SA08290168B1 (da) |
| SI (1) | SI2139557T1 (da) |
| WO (1) | WO2008116640A2 (da) |
| ZA (1) | ZA200906700B (da) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8926990B2 (en) | 2009-10-13 | 2015-01-06 | Rutgers, The State University Of New Jersey | Treatment and diagnosis of inflammatory disorders and HIV |
| ITPD20090279A1 (it) * | 2009-09-25 | 2011-03-26 | Hypothesis Srl | Dispositivo per la prevenzione della trombosi venosa profonda |
| DE102009060543B4 (de) * | 2009-12-23 | 2014-02-06 | Axel Muntermann | Verfahren zur kosmetischen Hautglättung |
| WO2012030248A1 (ru) * | 2010-09-03 | 2012-03-08 | Sajphutdinov Marat Kadirovich | Система электромагнитной бесконтактной терапии |
| ITBO20110125A1 (it) * | 2011-03-16 | 2012-09-17 | Project Di Gaudenzi Valter | Dispositivo per applicazioni al corpo |
| GB2486853B (en) * | 2011-04-18 | 2013-06-05 | Freewave Ltd | Therapeutic apparatus for irradiating biological cells |
| ITNA20110019A1 (it) * | 2011-04-28 | 2012-10-29 | Attilio Grattacaso | Apparecchiatura, sistema e metodo per la contrazione e la congiunta diatermia mediante modulazione e radiofrequenza |
| CN102353848B (zh) * | 2011-07-01 | 2013-08-28 | 大连海事大学 | 一种细胞用电磁辐射实验系统 |
| RU2514344C1 (ru) * | 2012-12-05 | 2014-04-27 | Государственное бюджетное образовательное учреждение высшего профессионального образования "Самарский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ГБОУ ВПО СамГМУ Минздрава России) | Способ вестибулопластики |
| WO2014164924A1 (en) * | 2013-03-11 | 2014-10-09 | NeuroEM Therapeutics, Inc. | Electromagnetic treatment of brian and body disorders |
| US11759650B2 (en) | 2013-03-11 | 2023-09-19 | NeuroEM Therapeutics, Inc. | Immunoregulation, brain detoxification, and cognitive protection by electromagnetic treatment |
| US11911629B2 (en) | 2013-03-11 | 2024-02-27 | NeurEM Therapeutics, Inc. | Treatment of primary and metastatic brain cancers by transcranial electromagnetic treatment |
| US11752356B2 (en) | 2013-03-11 | 2023-09-12 | NeuroEM Therapeutics, Inc. | Systems for controlling power to differently loaded antenna arrays |
| US12318624B2 (en) | 2013-03-11 | 2025-06-03 | NeuroEM Therapeutics, Inc. | Brain immunoregulation through transcranial electromagnetic treatment |
| US11813472B2 (en) * | 2013-03-11 | 2023-11-14 | NeuroEM Therapeutics, Inc. | Systems for sensing proper emitter array placement |
| ES2535696A1 (es) * | 2013-11-13 | 2015-05-13 | Joaquín SUROS FRIGOLA | Generador de ondas de AM y FM para la práctica de la electroterapia |
| US11794028B2 (en) | 2014-03-11 | 2023-10-24 | NeuroEM Therapeutics, Inc. | Transcranial electromagnetic treatment |
| US9784263B2 (en) | 2014-11-06 | 2017-10-10 | Zoll Circulation, Inc. | Heat exchange system for patient temperature control with easy loading high performance peristaltic pump |
| US11359620B2 (en) | 2015-04-01 | 2022-06-14 | Zoll Circulation, Inc. | Heat exchange system for patient temperature control with easy loading high performance peristaltic pump |
| US20160317050A1 (en) | 2015-04-28 | 2016-11-03 | Federico Perego Costa | Hemodynamic parameter (Hdp) monitoring system for diagnosis of a health condition of a patient |
| US11116657B2 (en) | 2017-02-02 | 2021-09-14 | Zoll Circulation, Inc. | Devices, systems and methods for endovascular temperature control |
| US11185440B2 (en) | 2017-02-02 | 2021-11-30 | Zoll Circulation, Inc. | Devices, systems and methods for endovascular temperature control |
| KR101845017B1 (ko) * | 2017-07-21 | 2018-04-03 | 주식회사 비엠텍월드와이드 | 구강용 고주파 치료기 |
| CN111565632B (zh) * | 2017-10-13 | 2024-06-28 | 奥特美医疗有限责任公司 | 用于表征、诊断并治疗患者的健康状况的系统和微管导电率以及其使用方法 |
| CN113382629A (zh) * | 2018-12-03 | 2021-09-10 | Aah控股有限责任公司 | 采用电磁场治疗精神和行为疾病和障碍的装置和方法 |
| CN113825447A (zh) * | 2019-04-10 | 2021-12-21 | 奥特美医疗有限责任公司 | 用于患者结局的预后预测的系统及其使用方法 |
| AU2020370043A1 (en) * | 2019-10-21 | 2022-04-28 | Therabionic Inc. | Electrical system for treatment of a subject |
| CN114761071A (zh) | 2019-12-11 | 2022-07-15 | 诺沃库勒有限责任公司 | 用于对细胞成像的合成物和方法 |
| EP4484949A3 (en) | 2019-12-11 | 2025-03-19 | Novocure GmbH | Compositions and methods of altering the electric impedance to an alternating electric field |
| US12076556B2 (en) | 2019-12-11 | 2024-09-03 | Novocure Gmbh | Compositions and methods of altering the electric impedance to an alternating electric field |
| CN115443171A (zh) | 2020-05-08 | 2022-12-06 | 诺沃库勒有限责任公司 | 向多能干细胞施加交变电场的组合物和方法 |
| KR102833919B1 (ko) | 2022-04-27 | 2025-07-15 | 한국전자통신연구원 | 개인 맞춤형 전기장 암 치료 방법 및 장치 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4649935A (en) * | 1984-05-21 | 1987-03-17 | Symtonic Sa | Method of treating neurovegetative disorders and apparatus therefor |
| US5441528A (en) * | 1992-09-25 | 1995-08-15 | Symtonic, S.A. | Method and system for applying low energy emission therapy |
| US6167304A (en) * | 1993-05-28 | 2000-12-26 | Loos; Hendricus G. | Pulse variability in electric field manipulation of nervous systems |
| JPH07171222A (ja) * | 1993-12-21 | 1995-07-11 | Olympus Optical Co Ltd | 温熱治療装置 |
| RU2112563C1 (ru) * | 1995-03-14 | 1998-06-10 | Синицын Лев Николаевич | Способ лечения гнойных ран |
| US5891182A (en) * | 1995-10-11 | 1999-04-06 | Regeneration Tech | Bio-active frequency generator and method |
| CA2227296C (en) * | 1995-10-11 | 2003-12-23 | Regeneration Technology | Bio-active frequency generator and method |
| US6246912B1 (en) * | 1996-06-27 | 2001-06-12 | Sherwood Services Ag | Modulated high frequency tissue modification |
| US5908441A (en) * | 1997-01-16 | 1999-06-01 | Bare; James E. | Resonant frequency therapy device |
| RU2127616C1 (ru) * | 1998-02-03 | 1999-03-20 | Закрытое акционерное общество НЦИМ "ЛИДО" | Устройство для миллиметрововолновой терапии |
| EP0966988A1 (en) | 1998-06-24 | 1999-12-29 | Santi Tofani | Apparatus and method for interfering with pathological cells survival |
| US20050090732A1 (en) * | 2003-10-28 | 2005-04-28 | Triton Biosystems, Inc. | Therapy via targeted delivery of nanoscale particles |
| JP4664661B2 (ja) * | 2004-12-15 | 2011-04-06 | 株式会社東芝 | 放射線治療管理システム |
-
2007
- 2007-03-27 EP EP07006320A patent/EP1974769A1/en not_active Withdrawn
-
2008
- 2008-03-26 BR BRPI0810084A patent/BRPI0810084B1/pt active IP Right Grant
- 2008-03-26 AU AU2008232041A patent/AU2008232041C1/en active Active
- 2008-03-26 CN CN200880009846.4A patent/CN101663065B/zh active Active
- 2008-03-26 SI SI200831475T patent/SI2139557T1/sl unknown
- 2008-03-26 WO PCT/EP2008/002379 patent/WO2008116640A2/en not_active Ceased
- 2008-03-26 JP JP2010500133A patent/JP5435240B2/ja active Active
- 2008-03-26 ES ES08734777.9T patent/ES2545103T3/es active Active
- 2008-03-26 EP EP08734777.9A patent/EP2139557B1/en active Active
- 2008-03-26 PL PL08734777T patent/PL2139557T3/pl unknown
- 2008-03-26 HU HUE08734777A patent/HUE027033T2/en unknown
- 2008-03-26 MX MX2009010425A patent/MX2009010425A/es active IP Right Grant
- 2008-03-26 PT PT87347779T patent/PT2139557E/pt unknown
- 2008-03-26 DK DK08734777.9T patent/DK2139557T3/da active
- 2008-03-26 KR KR1020097022489A patent/KR101474582B1/ko active Active
- 2008-03-26 US US12/450,450 patent/US20100042168A1/en not_active Abandoned
- 2008-03-26 CA CA2682322A patent/CA2682322C/en active Active
- 2008-03-26 RU RU2009139633/14A patent/RU2594824C2/ru active
- 2008-03-29 SA SA08290168A patent/SA08290168B1/ar unknown
-
2009
- 2009-09-22 IL IL201099A patent/IL201099A/en active IP Right Grant
- 2009-09-25 ZA ZA2009/06700A patent/ZA200906700B/en unknown
-
2012
- 2012-08-22 US US13/573,104 patent/US8977365B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2139557T3 (da) | Elektronisk system til påvirkning af cellulære funktioner hos et varmblodet pattedyrindivid | |
| EP3749409B1 (en) | Tissue-stimulating device using frequency scanning of electric and magnetic fields | |
| JP5840774B2 (ja) | 埋込可能な医学治療送達装置のファーフィールド放射電力供給 | |
| Habibagahi et al. | Vagus nerve stimulation using a miniaturized wirelessly powered stimulator in pigs | |
| WO2002102457A1 (en) | Apparatus for applying an electromagnetic field to a living body | |
| US20220379130A1 (en) | Electrical system for treatment of a subject | |
| OA20699A (en) | Electrical system for treatment of a subject | |
| EA048348B1 (ru) | Электрическая система для лечения субъекта | |
| Levendag et al. | Interstitial radiation and/or interstitial hyperthermia for advanced and/or recurrent cancers in the head and neck: a pilot study | |
| CN101332337A (zh) | 一种物理疗法治疗仪及其操作方法 | |
| WO2004014485A1 (en) | Electromagnetic wave therapy treatment method and apparatus |